Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product

Receives First Milestone Payment for NXP001

Cambridge, UK, 27 November 2018: ​​Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma (“NSB”), its Chinese licensing partner for NXP001, which is in development for cancer supportive care.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...